PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-12.41%
Revenue decline while RVPH shows 0.00% growth. Joel Greenblatt would examine competitive position erosion.
No Data
No Data available this quarter, please select a different quarter.
-12.41%
Gross profit decline while RVPH shows 0.00% growth. Joel Greenblatt would examine competitive position.
No Data
No Data available this quarter, please select a different quarter.
29.66%
R&D growth less than half of RVPH's 280.24%. David Dodd would verify if efficiency advantage is sustainable.
16.61%
G&A growth while RVPH reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
25.48%
Operating expenses growth 50-75% of RVPH's 38.36%. Bruce Berkowitz would examine efficiency.
25.48%
Total costs growth 50-75% of RVPH's 38.36%. Bruce Berkowitz would examine efficiency.
No Data
No Data available this quarter, please select a different quarter.
3.10%
D&A growth while RVPH reduces D&A. John Neff would investigate differences.
-28.10%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
-46.25%
EBITDA margin decline while RVPH shows 0.00% growth. Joel Greenblatt would examine position.
-27.47%
Both companies show declining income. Martin Whitman would check industry conditions.
-45.52%
Operating margin decline while RVPH shows 0.00% growth. Joel Greenblatt would examine position.
-14.81%
Other expenses reduction while RVPH shows 5.88% growth. Joel Greenblatt would examine advantage.
-27.92%
Both companies show declining income. Martin Whitman would check industry conditions.
-46.04%
Pre-tax margin decline while RVPH shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-27.92%
Both companies show declining income. Martin Whitman would check industry conditions.
-46.04%
Net margin decline while RVPH shows 0.00% growth. Joel Greenblatt would examine position.
-20.00%
EPS decline while RVPH shows 0.00% growth. Joel Greenblatt would examine position.
-20.00%
Diluted EPS decline while RVPH shows 0.00% growth. Joel Greenblatt would examine position.
6.47%
Share count reduction exceeding 1.5x RVPH's 43.34%. David Dodd would verify capital allocation.
6.47%
Diluted share reduction exceeding 1.5x RVPH's 43.34%. David Dodd would verify capital allocation.